Stabilization & Maintenance

This paper outlines many important considerations in delivering medical psychiatric crisis care and provides information and recommendations to improve practices and ultimately better meet the needs of individuals served.

This correspondence provides updates on the May 2023 Xylazine Exposure Guidance and discusses implications for clinical practice and frontline public health.

This article reviews a recent study that evaluated if acces to rewarding, fun activities operates as a protective factor for people receiving treatment for substance use difficulties.

This article reviews medication for opioid use disorder (MOUD) treatments in the United States from data pulled from the 2022 National Survey on Drug Use and Health.

This on-demand webinar reviews research on 12-step mutual help groups for people seeking to recovery from addiction and discusses the mechanisms through which 12-step groups affect members.

This Topic Brief provides an overview of what constitutes low-threshold treatment for patients with OUD, the state of the evidence and patient perspectives on low-threshold OUD treatment, and key steps and strategies for providing low-threshold treatment for patients with OUD in primary care settings.

This virtual public meeting which explored real-world experiences and scientific evidence for buprenorphine initiation strategies, as well as medication dosing and management during continued treatment across different care settings

This fact sheet provides an overview of the Medication First (or low-barrier maintenance pharmacotherapy) approach to the treatment of opioid use disorders.

This resource document provides practical, evidence-based information for primary care providers and practices on prescribing buprenorphine to individuals in need of intervention, including implementation considerations and strategies for primary care providers and primary care organizations.

This SAMHSA page includes information on 2023 training requirements that eliminated the DATA waiver that was previously needed to prescribe buprenorphine and expanded the number of DEA-registered practitioners able to treat people with opioid use disorder.